Patent
The present invention relates to Lawsonia intracellularis vaccines and methods for protecting against and diagnosing L. intracellularis infection. The products and processes of the invention are attainable, in part, as the result of an improved method for cultivating large scale supplies of L. intracellularis , including both a novel isolate of L. intracellularis of European origin and a method of preparing a lyophilized product containing the attenuated European isolate as vaccine product.
1. An avirulent isolate of Lawsonia intracellularis , wherein said avirulent isolate is Lawsonia intracellularis deposit isolate ATCC No. PTA-4926.
2. A vaccine for the immunization of an animal, comprising a pharmaceutically effective amount of the avirulent isolate of Lawsonia intracellularis according to claim 1 , and a pharmaceutically acceptable carrier.
3. The vaccine according to claim 2 wherein the pharmaceutically effective amount of the avirulent isolate of Lawsonia intracellularis is about 10 3 TCID 50 to about 10 6 TCID 50 per dose.
4. A vaccine for the immunization of an animal, comprising the avirulent isolate of Lawsonia intracellularis according to claim 1 and antigenic material from at least one of the following pathogens: Salmonella spp., Erysipelothrix spp., Haemophilus spp., Mycoplasma spp., Leptospira spp., Clostridium spp., Streptococcus spp., Brachyspira spp., circovirus, porcine reproductive and respiratory syndrome (PRRS) virus, swine influenza virus (SIV), transmissible gastro-enteritis (TGE) virus, parvovirus, or Escherichia coli ; and a pharmaceutically acceptable carrier.
5. A vaccine for the immunization of an animal, comprising the avirulent isolate of Lawsonia intracellularis according to claim 1 and antigenic material from Salmonella choleraesuis, Eysipelothrix spp. transmissible gastro-enteritis (TGE) virus, Escherichia coli, Clostridium spp., and Brachyspira spp.; and a pharmaceutically acceptable carrier.
6. A vaccine for the immunization of an animal, comprising the avirulent isolate of Lawsonia intracellularis according to claim 1 and antigenic material from Salmonella choleraesuis and Erysipelothrix spp.; and a pharmaceutically acceptable carrier.
7. A vaccine for the immunization of an animal, comprising the avirulent isolate of Lawsonia intracellularis according to claim 1 and antigenic material from at least one of the following pathogens: Clostridium spp., equine influenza virus (EIV), equine herpes virus (EHV), alphavirus, and West Nile virus; and a pharmaceutically acceptable carrier.